Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554107 | 1.00 | MAOB (0.37) | MAOBGAAATMCCNT1CDK9 | |
| SCHEMBL25380108 | 0.88 | MAOB (0.41) | MAOBGAARXFP1MAPTABCB1 | |
| SCHEMBL30554096 | 0.73 | ABCB1 (0.36) | MAOBMAPTPOLBABCB1ALDH1A1 | |
| SCHEMBL9950354 | 0.72 | CA2 (0.52) | ATMCCNT1CDK9POLBALDH1A1 | |
| SCHEMBL30477927 | 0.72 | CA2 (0.52) | ATMCCNT1CDK9POLBALDH1A1 | |
| SCHEMBL30554093 | 0.71 | NPY5R (0.32) | KMT2A | |
| SCHEMBL15839224 | 0.71 | STING1 (0.43) | GAAATMCCNT1CDK9MAPT | |
| SCHEMBL30423345 | 0.71 | NPY5R (0.32) | — | |
| SCHEMBL21768002 | 0.68 | CA2 (0.47) | GAAATMMAPTPOLBABCB1 | |
| SCHEMBL27813654 | 0.68 | CA2 (0.50) | GAAATMMAPTPOLBABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177579-A1 | NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-06-05 | — | — | US | disclosed |
| EP-4484425-A1 | NOVEL COMPOUND, ALPHA-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | National Institutes for Quantum Science and Technology (JP) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023163033-A1 | NOVEL COMPOUND, α-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | 国立研究開発法人量子科学技術研究開発機構 | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177579-A1 | NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | SNCA, PARK7, LRRK2 | MAOB 2178/4885GAA 396/4885ATM 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.